Indications and medication precautions of French HAR version of Metirapone
Metirapone is mainly used for the diagnosis and treatment of Cushing's syndrome, exerting its effects by inhibiting the synthesis of adrenal cortex hormones. The indications are clear, but medication must strictly follow the precautions to ensure safety and effectiveness. The following text will provide a detailed explanation of indications and key medication precautions.
1. Indications
(1) Diagnosis of Cushing's syndrome: As an adjuvant medication for the adrenocorticotropic hormone (ACTH) stimulation test, the diagnosis is assisted by measuring urinary 17 hydroxycorticosteroid levels.
(2) Cushing's syndrome treatment: Used for Cushing's syndrome patients who are unable to undergo surgery or radiation therapy, to alleviate symptoms by inhibiting cortisol synthesis.
2. Medication precautions
(1) Dose adjustment: The initial dose should be individualized and gradually adjusted according to the level of 17 hydroxycorticosteroids in urine to avoid excessive inhibition of adrenal function.
(2) Monitoring requirements: Regularly monitor electrolytes, blood pressure, and adrenal function during treatment to be alert to signs of adrenal insufficiency.
(3) Taboo population: Pregnant women are prohibited from using it; Use with caution in patients with severe liver and kidney dysfunction; Prohibited for individuals allergic to drug ingredients.
3. Medication for special populations
(1) Pregnancy: May interfere with fetal adrenal development. Women of childbearing age should confirm that they are not pregnant and take reliable contraceptive measures.
(2) Breastfeeding period: It is not clear whether the medication is secreted through breast milk. It is recommended to suspend breastfeeding during the medication period.
(3) Elderly people are more prone to adverse reactions such as hypotension, and need to strengthen monitoring and consider reducing dosage.
4. Drug interactions
(1) Liver enzyme inducers, such as sodium phenytoin and rifampicin, may reduce the efficacy of metoprolol and should be avoided in combination or adjusted in dosage.
(2) Central nervous system inhibitors: may enhance sedative effects, caution should be exercised and neurological symptoms monitored when used in combination.
Disclaimer：《Indications and medication precautions of French HAR version of Metirapone》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！